Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Divalproex Sodium Clear all
Withdrawn Phase 2 Interventional

Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

NCT00204503
View directory record Official record
Conditions
Bipolar I or II Depression and Alcohol Abuse or Dependence
Interventions
Depakote ER
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 20, 2026, 3:30 PM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Tolerability and Efficacy of Depakote-extended Release in the Elderly

NCT00318929
View directory record Official record
Conditions
Elderly, Epilepsy, Seizures
Interventions
Divalproex Sodium Extended-Release Tablets
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

NCT00221975
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex, Lamotrigine, Lithium
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional

Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults

NCT00218114
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse
Interventions
Divalproex Sodium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 20, 2026, 3:30 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional

Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

NCT00278772
View directory record Official record
Conditions
Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania
Interventions
Divalproex, Placebo
Drug · Other
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Not applicable Interventional Results available

Valproate for Mood Swings and Alcohol Use Following Head Injury

NCT01760785
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Alcoholism
Interventions
divalproex sodium, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 20, 2026, 3:30 PM EDT
Terminated Phase 4 Interventional

Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder

NCT00203385
View directory record Official record
Conditions
PTSD
Interventions
Divalproex
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 20, 2026, 3:30 PM EDT
Terminated Not applicable Interventional Results available

Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

NCT00665444
View directory record Official record
Conditions
Bipolar Disorder, Metabolic Syndrome
Interventions
Aripiprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 2Phase 3 Interventional

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514
View directory record Official record
Conditions
Alcoholism, Alcohol Related Disorders, Mood Disorders
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Effect of Lithium and Divalproex in Alzheimer's Disease

NCT00088387
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Divalproex, Lithium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

NCT00402324
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
olanzapine, placebo, divalproex
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 20, 2026, 3:30 PM EDT
Withdrawn Phase 2 Interventional

A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

NCT01170325
View directory record Official record
Conditions
Autism, Autism Spectrum Disorders
Interventions
Divalproex Sodium, Placebo Comparator
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

NCT01358357
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

NCT01183676
View directory record Official record
Conditions
Healthy
Interventions
DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 4 Interventional Results available

Iloperidone in Mixed States of Bipolar Disorder

NCT02413918
View directory record Official record
Conditions
Bipolar Disorder
Interventions
iloperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

NCT01575561
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

NCT01284517
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Costa Mesa, California • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 3 Interventional

Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine

NCT00195806
View directory record Official record
Conditions
Migraine
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2007 · Synced Oct 20, 2026, 3:30 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 20, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

NCT00206778
View directory record Official record
Conditions
Mixed Mania Bipolar Disorder
Interventions
Lamotrigine, Sodium Valproate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 20, 2026, 3:30 PM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 20, 2026, 3:30 PM EDT